Skip to main content

Medical Disclaimer: GLP-1 Primer is an educational resource, not a medical provider. We do not offer medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting any medication.

New IndicationsNEW

FDA Approves Foundayo (orforglipron) as First Once-Daily Oral GLP-1 for Obesity

The FDA approved Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for the treatment of obesity and overweight with weight-related comorbidities. Unlike other oral GLP-1 options, it does not require specific food or water restrictions for administration.

Development date: Apr 1, 2026Verified by GLP-1 Primer: Aug 7, 2026

Why This Matters

Editorial interpretation

This approval introduces a new oral delivery method for GLP-1 therapy, potentially increasing patient convenience and access by removing the need for injections and specific fasting requirements associated with other oral GLP-1 medications.

What Changed / What We Know

A new therapeutic option has been added to the market for obesity management, providing an alternative to injectable GLP-1 therapies.

Editorial note

GLP-1 Primer is an independent educational resource, not a medical provider. This update summarizes a public development and is not medical advice. Always consult a licensed healthcare professional before starting, changing, or stopping any medication. Pricing details, where present, reflect the context noted and may not be universally available.

Last reviewed: Aug 7, 2026

base44
Edit with Base44